Emerging evidence have illustrated the vital roles of long noncoding RNAs (lncRNAs) in glioma. Nevertheless, the majority of their roles and mechanisms in gliomagenesis are still largely unclear. In this study, we investigate the roles of lncRNA CASC9 on glioma tumourigenesis and authenticate its potential mechanisms. Results manifested that CASC9 was highly expressed in glioma specimens and cells, moreover, the ectopic overexpression was correlated with glioma patients' clinic. Functional studies found that siRNA-mediated CASC9 silencing inhibited the proliferative ability, invasion in vitro, and impaired the tumour growth in vivo. Mechanical studies revealed that miR-519d both targeted the 3′-UTR of CASC9 and STAT3 mRNA, which was identified by luciferase reporter assay and RNA immunoprecipitation (RIP). Moreover, chromatin immunoprecipitation (ChIP) and luciferase reporter assay revealed that STAT3, an oncogenic transcription factor, could bind with the promoter of CASC9 and activate its transcriptional level. In conclusion, our results concluded that CASC9 promotes STAT3 expression via sponging miR-519d, in return, STAT3 activate CASC9 transcription, forming a positive feedback loop of CASC9/ miR-519d/STAT3. The novel finding provides a potential therapeutic target for glioma.
| INTRODUCTION
Glioma is one of the most common human malignant tumour, moreover, it acts as the aggressive tumour and primary brain tumour in the central nervous system. 1, 2 Glioma, accounting for 70% of brain tumours, causes thousands of cancer-related death worldwide.
Despite the combination therapy, eg, surgical excision, chemotherapy, and radiotherapy, have significantly improved the long-term curative effect and prognosis, the survival rate and curative ratio is still pessimistic. 3 Glioma is characterized by high invasive and diffusion, yet the potential mechanisms remain far from understanding. 4 So, it is urgently needed to discover the molecular mechanisms of glioma tumourigenesis.
Long noncoding RNAs (lncRNAs) are a group of RNA with longer than 200 nucleotides, however, without protein-coding potential. In decades, noncoding RNAs (ncRNAs) are considered as the transcriptional byproducts without biological roles on pathophysiological processes. [5] [6] [7] However, with the help of next-generation sequencing Hongjiang Liu is the first author for this article.
(NGS) and bioinformatics tools, the crucial roles of lncRNAs have been wildly recognized. 8, 9 The dysregulation of lncRNAs regulates the transcriptional regulation or post-transcriptional regulation. For instance, lncRNA LINC00958 is significantly up-regulated in glioma tissues and cell lines compared with that of adjacent normal brain tissues, and the overexpression acts as an oncogenic gene in the gliomagenesis through miR-203-CDK2 regulation. 10 LncRNA HOXA11-AS is upregulated in glioma tissue and cell lines and the high HOXA11-AS expression indicates shorter survival and poorer prognosis.
11
It has been clearly reported that lncRNA CASC9 (Cancer Susceptibility Candidate 9) have been identified to contribute to the initiation and progression of several human cancers, including oesophageal cancer, lung adenocarcinoma and so on, involving in proliferation, invasion, metastasis. 12, 13 In present study, our team aim to uncover the role of CASC9 in the glioma tumourigenesis, presenting the ectopic overexpression of CASC9 in the progression by which accelerates the gliomagenesis by targeting miR-519d/STAT3 positive feedback loop. and reverse, 5′-GCCCAATACGACCAAATCC-3′.
| MATERIALS AND METHODS

| Clinical tissue samples
| Cellular proliferation assays
The proliferation assay was conducted using CCK-8 assay and colony formation assay. Cell viability was tested by Cell Counting Kit-8
(Dojindo) to the manufacturer's instructions. For colony formation, cells (1 × 10 3 ) were resuspended in medium and plated onto a bottom layer. After 14 days, the clones that larger than 0.5 mm were counted.
| Transwell invasion assay
The invasive ability of glioma cells was evaluated using transwell 
| Subcellular fractionation assay
The RNA was extracted from nuclear or cytoplasm fraction was measured using RT-qPCR analysis. U6, GAPDH acted as the nuclear or cytoplasm fractions using Nuclear and Cytoplasmic Extraction
Reagents (Thermo Scientific, USA).
| 6339
| Dual-luciferase reporter assay
The sequences containing the wild-type or mutant sites targeting miR-99 of CASC9 and STAT3 3′-Untranslated Region (UTR) were cloned into the pGL3-basic vector (Promega, USA) to construct the pGL3-CASC9
wild/mutant, and pGL3-STAT3 wild/mutant. Besides, the sequences containing CASC9 promoter region was also cloned into the pGL3-basic vector (Promega). All reporter vectors were cotransfected with miRNAs or negative controls into 293T cells. After 48 hours, luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega).
| RNA immunoprecipitation
RIP assay was done following Magna-RIP RNA Binding Immunoprecipitation Kit (Millipore, Bedford, MA, USA) as previous described.
Briefly, cells lysis was eluted and incubated with RIP buffer. AntiAgo2 antibody (Millipore) or negative control normal Mouse IgG (Millipore) was conjugated with magnetic beads. Subsequently, the enrichment in immunoprecipitation was measured using PCR.
| Chromatin immunoprecipitation
ChIP assay was conducted according to EZ ChIP Chromatin Immunoprecipitation Kit (Millipore, Bedford, MA, USA) as prior described. Briefly, anti-STAT3 antibody (Millipore) was used to immunoprecipitate the chromatin, and immunoglobulin G (IgG) was used as negative control.
Lastly, the enrichment of isolated RNA was tested using RT-PCR,
| In vivo xenograft assay
BALB/c nude mice (4-5 weeks) were purchased and maintained under specific pathogen-free conditions. About 1 × 10 7 cells/ml (0.1 ml) glioma cells (U87) were subcutaneously injected into flank of mice.
Tumour volume was calculated according to the following formula: 
| Statistical analysis
All results are presented as the mean ± SD by three independent assays. The significance between two groups was calculated using student's t test and one way ANOVA. Survival rate was calculated using Kaplan-Meier analysis and log-rank test. P-values <0.05 was considered as statistically significant.
| RESULTS
| LncRNA CASC9 is highly expressed in glioma tissue
As a first attempt to explore whether lncRNA CASC9 participated the pathogenesis of glioma, we measured the expression level of lncRNA CASC9 to identify whether it was aberrantly expressed in glioma tissue specimen. Results revealed that CASC9 expression was markedly overexpressed in the collected glioma tissue specimens compared with adjacent normal tissue ( Figure 1A ). Among these glioma tissue specimens, CASC9 expression was markedly up-regulated in advanced pathological type (WHO III-IV) than that of primary pathological type (WHO I-II) ( Figure 1B ). In conclusion, our results indicate that lncRNA CASC9 is highly expressed in glioma tissue. 
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| miR-519d directly targeted the 3′-UTR of CASC9
To identify the underlying mechanism that CASC9 accelerated the tumourigenesis of glioma, we sequentially performed mechanical experiments. Subcellular fractionation assay revealed that the subcellular location of CASC9 was mainly located in cytoplasm (Figure 3A) . Bioinformatics online tools (LNCipedia, https://lncipedia. org/) manifested that there were several complementary binding sites of miR-519d with the 3′-UTR of CASC9 ( Figure 3B ). To confirm the binding, luciferase activity assay was conducted and revealed that miR-519d could directly target with the 3′-UTR of CASC9 ( Figure 3C ). Following RIP assay revealed that miR-519d and CASC9 were both enriched in the immunoprecipitation, suggesting the incorporation within RNA-induced silencing complex (RISC) ( Figure 3D ). RT-PCR revealed that miR-519d expression level was decreased in U87 and U251 cells ( Figure 3E ), besides, it was increased in U87 and U251 cells transfected with si-CASC9 (Figure 3F) . Overall, data revealed that miR-519d directly targeted the 3′-UTR of CASC9.
| STAT3 acted as the target of miR-519d/ CASC9
In order to test the role of miR-519d and CASC9 on glioma, we further discovered the downstream target of miR-519d. Bioinformatics tools (TargetScan, http://www.targetscan.org) revealed that STAT3 might function as the downstream target of miR-519d utilizing the complementary binding sites ( Figure 4A ). To confirm the binding, luciferase activity assay was conducted and revealed that miR-519d could directly target with the 3′-UTR of STAT3 mRNA ( Figure 4B ).
RT-PCR analysis illustrated that STAT3 mRNA expression level was markedly increased in U87 and U251 cells ( Figure 4C ). In U87 cells, STAT3 mRNA expression level was markedly increased when transfected with miR-519d inhibitor ( Figure 4D ). Western blot analysis revealed that si-CASC9 transfection could significantly decreased the STAT3 protein level, while the cotransfection of si-CASC9 and miR519d inhibitor recovered the expression of STAT3 protein (Figure 4E,F) . Overall, these evidence could powerfully supported that STAT3 acted as the target of miR-519d/CASC9, suggesting the pathway of CASC9-miR-519d-STAT3.
| STAT3 accelerated CASC9 expression through binding with its promoter
In subsequent experiments, we continued to investigate whether transcription factor STAT3 was closely correlated with lncRNA CASC9. Based on Jaspar (http://jaspar.genereg.net), we predicted that STAT3 had potential binding sites with CASC9 promoter, including two binding sites with high possibility at the upstream of CASC9 (about −2000 to +1 bp) ( Figure 5A ). In U87 cell, the up-regulated STAT3 recombinant plasmid could markedly increase STAT3
protein expression level ( Figure 5B ). RT-PCR revealed that STAT3
up-regulation could increase CASC9 expression ( Figure 5C ). ChIP analysis showed that the binding affinity in second site (P2) is significantly higher, indicating the direct binding within STAT3 and CASC9 promoter ( Figure 5D ). Luciferase reporter assay revealed that CASC9
wild-type had high activity with STAT3 ( Figure 5E ). Therefore, results concluded that STAT3 accelerated CASC9 expression through binding with its promoter.
| DISCUSSION
Growing evidence have revealed that approach 3000 human lncRNAs are exist in the genome, however, only less than 1% have been characterized. 14 Numerous literature have indicated that lncRNAs were vital elements in human tumourigenesis. LncRNA CASC9 (Cancer Susceptibility Candidate 9) have been identified to contribute to the initiation and progression of several human cancers, including oesophageal cancer, lung adenocarcinoma, and so on.
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The increasing vital roles of lncRNAs have been involved in more and more extensive fields, including human tumours, cardiovascular and/or miR-519d inhibitor. *P < 0.05, **P < 0.01 compared to control group. ns presented no significant difference system disorder, or metabolic diseases. [15] [16] [17] [18] [19] In this study, our data concluded that CASC9 was dramatically high-expressed in glioma tis- , P2 ). E, Luciferase reporter assay revealed the activity within STAT3 and CASC9 wild-type or mutant. *P < 0.05, **P < 0.01 compared to control group
